Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

×

Skip to main content

Laser Ablation Indications

Putting a cure within reach

The Visualase™ system has the potential to cure, not just treat, patients with epilepsy and brain tumours. Could your patient be eligible for this possibly life-changing treatment?

The Visualase™ system uses MRI-guided laser ablation to perform Laser Interstitial Thermal Therapy (LITT). With the smallest laser catheter on the market1-4, brain tumours and epileptic foci can be ablated with unmatched surgical precision, in a minimally-invasive procedure.

Approved indications

The Visualase™ MRI-Guided Laser Ablation System is indicated for use as a minimally-invasive procedure to ablate, necrotise or coagulate soft tissue through interstitial irradiation or thermal therapy under magnetic resonance imaging (MRI) guidance for wavelengths 800nm through 1064nm in cranial neurosurgery.

View clinical research, understand patient selection, and discover how the Visualase™ system could help your patients with the following indications.

Brain tumour

The Visualase™ system is a minimally invasive surgical option to ablate tumours in the brain. The unmatched surgical precision of LITT makes it possible to access deep-seated brain tumours that may otherwise be considered inoperable.5

Learn more

Epilepsy

Between 11% and 41% of epilepsy cases are drug resistant.6-11 The Visualase™ system has the potential to irreversibly ablate epileptic foci, which changes what is possible for patients with drug-resistant epilepsy.
 

Learn more

Radiation necrosis

LITT can arrest the progression of radiation necrosis that may have resulted from earlier radiation therapy.12

 

 

Learn more

Better support

We can help you find a treatment option that is right for your patient. Our team is here to support you with the information you need to make the most informed decisions for your patient’s care.

Sign up to be contacted by a Medtronic representative for more customised support, to be notified of educational opportunities, and to hear about our latest product innovations.

Contact Us

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

Brief statement:
See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at www.medtronic.eu.
  1. Yuen J et al, 2014, Stereotact Funct Neurosurg. 92(3):160-169. doi:10.1159/000360862.
  2. Hawasli et al, 2012, Operative Neurosurgery, 70:onsE332-onsE338. doi:10.1227/NEU.0b013e318232fc90.
  3. Mohammadi et al, 2014, Expert Review of Medical Devices, 11(2):109-119. doi:10.1586/17434440.2014.882225.
  4. Monteris Medical, 2023, https://www.prnewswire.com/news releases/monteris-medical-announces-launch-of-fda-cleared-neuroblate-sidefire-select-and fullfire-select-reduceddiameter-laser-mini-probes-for-minimally-invasive-robotic-laser thermotherapy-300075653.html. Accessed May 31, 2023.
  5. Ivan et al, 2016, Neurosurgery, 79(Supplement 1):S17-S23. doi:10.1227/NEU.0000000000001446
  6.  Kwan et al, 2000, N Eng l J Med, 342(5):314-319
  7. Hui et al, 2007, Clinical Neurology and Neurosurgery, 109(8):672-675
  8. Picot et al, 2008, Epilepsia, 49(7):1230-1238
  9. Mohanraj et al, 2006, EurJNeurol, 13(3):277-282
  10. Giussani et al, 2016, Epilepsy Behav, 55:30-37
  11. Chen et al, 2013, Journal of Medical Economics, 16(2):240-248
  12. Hernandez et al, 2019, Neurosurg. 85(1):84-90. doi:10.1093/neuros/nyy220
Visualase CE Mark